Citadel Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.8M | Buy |
125,950
+16,050
| +15% | +$3.09M | ﹤0.01% | 2065 |
|
|
2025
Q4 | $20.2M | Buy |
109,900
+1,700
| +2% | +$298K | ﹤0.01% | 2327 |
|
|
2025
Q3 | $16.6M | Sell |
108,200
-72,450
| -40% | -$11M | ﹤0.01% | 2576 |
|
|
2025
Q2 | $25.2M | Buy |
180,650
+55,000
| +44% | +$7.71M | ﹤0.01% | 1879 |
|
|
2025
Q1 | $18.5M | Sell |
125,650
-307,900
| -71% | -$44.5M | ﹤0.01% | 2134 |
|
|
2024
Q4 | $56.8M | Buy |
433,550
+269,500
| +164% | +$37.7M | 0.01% | 1169 |
|
|
2024
Q3 | $25.6M | Buy |
164,050
+20,700
| +14% | +$3.34M | ﹤0.01% | 1805 |
|
|
2024
Q2 | $22.4M | Sell |
143,350
-705,350
| -83% | -$106M | ﹤0.01% | 1882 |
|
|
2024
Q1 | $115M | Buy |
848,700
+388,450
| +84% | +$51.4M | 0.02% | 625 |
|
|
2023
Q4 | $62M | Sell |
460,250
-246,950
| -35% | -$32.1M | 0.01% | 1019 |
|
|
2023
Q3 | $95.8M | Buy |
707,200
+148,550
| +27% | +$20.3M | 0.02% | 649 |
|
|
2023
Q2 | $80M | Buy |
558,650
+259,400
| +87% | +$38.2M | 0.02% | 754 |
|
|
2023
Q1 | $41.5M | Buy |
299,250
+5,174
| +2% | +$696K | 0.01% | 1229 |
|
|
2022
Q4 | $39.9M | Sell |
294,076
-120,700
| -29% | -$15.1M | 0.01% | 1304 |
|
|
2022
Q3 | $45.5M | Buy |
414,776
+41,050
| +11% | +$5.21M | 0.01% | 1147 |
|
|
2022
Q2 | $49.4M | Buy |
373,726
+44,306
| +13% | +$5.81M | 0.01% | 1029 |
|
|
2022
Q1 | $43.7M | Sell |
329,420
-594,042
| -64% | -$71.2M | 0.01% | 1217 |
|
|
2021
Q4 | $108M | Sell |
923,462
-133,244
| -13% | -$15.7M | 0.02% | 619 |
|
|
2021
Q3 | $127M | Sell |
1,056,706
-78,494
| -7% | -$9.14M | 0.03% | 544 |
|
|
2021
Q2 | $136M | Buy |
1,135,200
+18,150
| +2% | +$1.99M | 0.03% | 513 |
|
|
2021
Q1 | $111M | Buy |
1,117,050
+330,650
| +42% | +$33.2M | 0.03% | 535 |
|
|
2020
Q4 | $78.6M | Buy |
786,400
+496,050
| +171% | +$52.5M | 0.02% | 678 |
|
|
2020
Q3 | $31.8M | Buy |
290,350
+173,850
| +149% | +$19.3M | 0.01% | 1167 |
|
|
2020
Q2 | $12.3M | Buy |
116,500
+1,900
| +2% | +$196K | ﹤0.01% | 1991 |
|
|
2020
Q1 | $10.2M | Sell |
114,600
-4,800
| -4% | -$452K | ﹤0.01% | 1825 |
|
|
2019
Q4 | $11.9M | Buy |
119,400
+39,900
| +50% | +$3.76M | 0.01% | 2024 |
|
|
2019
Q3 | $7.09M | Sell |
79,500
-1,100
| -1% | -$95.4K | ﹤0.01% | 2649 |
|
|
2019
Q2 | $6.65M | Buy |
80,600
+3,150
| +4% | +$247K | ﹤0.01% | 2697 |
|
|
2019
Q1 | $6.26M | Buy |
77,450
+33,000
| +74% | +$2.6M | ﹤0.01% | 2675 |
|
|
2018
Q4 | $3.38M | Buy |
44,450
+13,100
| +42% | +$1.02M | ﹤0.01% | 3351 |
|
|
2018
Q3 | $2.48M | Sell |
31,350
-15,300
| -33% | -$1.16M | ﹤0.01% | 4033 |
|
|
2018
Q2 | $3.28M | Sell |
46,650
-15,200
| -25% | -$1.09M | ﹤0.01% | 3345 |
|
|
2018
Q1 | $4.33M | Sell |
61,850
-23,150
| -27% | -$1.6M | ﹤0.01% | 2624 |
|
|
2017
Q4 | $5.9M | Buy |
85,000
+6,100
| +8% | +$411K | ﹤0.01% | 2284 |
|
|
2017
Q3 | $5.35M | Sell |
78,900
-57,150
| -42% | -$3.61M | ﹤0.01% | 2242 |
|
|
2017
Q2 | $9.28M | Buy |
136,050
+108,450
| +393% | +$7.08M | 0.01% | 1516 |
|
|
2017
Q1 | $1.72M | Sell |
27,600
-34,750
| -56% | -$2.02M | ﹤0.01% | 3240 |
|
|
2016
Q4 | $3.41M | Sell |
62,350
-400
| -0.6% | -$22.7K | ﹤0.01% | 2365 |
|
|
2016
Q3 | $4.12M | Buy |
62,750
+13,600
| +28% | +$889K | ﹤0.01% | 2170 |
|
|
2016
Q2 | $2.97M | Buy |
+49,150
| New | +$2.85M | ﹤0.01% | 2330 |
|
Other funds holding AZN
IA
VCM
VAM
Citadel Advisors's AZN Position: Q1 2026 in Review
Citadel Advisors increased its AstraZeneca (AZN) stake by 345% in Q1 2026, buying an estimated $280M and bringing the position to 1,869,793 shares worth $369M. The position accounts for 0.06% of the portfolio, ranked #251.
Citadel Advisors first reported a position in AZN in Q2 2013 and has held it in 50 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Citadel Advisors held 1,869,793 shares of AstraZeneca worth $369M as of Q1 2026.
- Citadel Advisors bought 1,449,726 AstraZeneca shares in Q1 2026, an estimated $280M.
- AstraZeneca made up 0.06% of Citadel Advisors's portfolio in Q1 2026, its #251 holding.
- Citadel Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 50 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.